Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
About Chromadex Corp
Chromadex Corp (CDXC) is a globally recognized integrated nutraceutical and bioscience company committed to improving the quality of life through advanced research on healthy aging. The company is deeply invested in understanding the mechanisms by which cellular processes, particularly those involving nicotinamide adenine dinucleotide (NAD+), impact the aging process. With a core focus on innovative science, Chromadex has developed a multifaceted business model that spans from research breakthroughs to commercially available consumer products, ensuring that its scientific discoveries translate into meaningful daily benefits.
Business Model and Core Segments
Chromadex’s operational framework is built on three primary segments that work in unison to deliver high-quality, science-based nutraceutical innovations:
- Consumer Products: This segment is primarily responsible for marketing and distributing products directly to the consumer market. Its portfolio features formulations designed to support healthy aging by leveraging proprietary, scientifically validated ingredients. The company’s flagship product, built around the NAD+ precursor nicotinamide riboside (NR), exemplifies its commitment to translating rigorous research into everyday solutions.
- Ingredients Segment: Focused on the development and licensing of novel ingredients, this segment utilizes high-caliber scientific research to create bioactive compounds. These innovations are targeted for use in various applications, ranging from dietary supplements to functional foods, ensuring that the expertise of Chromadex is shared widely across the industry.
- Analytical Reference Standards and Services: This area underpins the rigorous quality control and analytical validation processes that are crucial to research and product development. By offering specialized standards and services, Chromadex supports both internal development and external quality assurance needs in a scientifically robust manner.
Research and Innovation
At the heart of Chromadex’s operations is a steadfast commitment to research and development. The company partners with leading universities and research institutions worldwide to explore the potential of critical biochemical pathways related to aging. This collaborative approach not only strengthens its research capabilities but also ensures that the ingredients developed are based on solid scientific evidence. The integration of cutting-edge bioscience and precise analytical methodologies solidifies its position as a trusted name in the nutraceutical industry.
Market Position and Competitive Differentiation
Chromadex distinguishes itself by focusing on the intersection of scientific innovation and consumer wellness. Its emphasis on NAD+ research, an area that has increasingly become synonymous with the study of aging and cellular health, sets it apart in a competitive landscape that includes various bioscience and nutraceutical companies. The company’s multidimensional approach, which bridges direct consumer engagement with deep scientific inquiry, provides a unique value proposition that caters both to health-conscious individuals and to industry partners seeking high-quality, science-backed ingredients.
Commitment to Transparency and Quality
Transparency in research and product development is a core tenet of Chromadex’s philosophy. Every stage of its process—from initial scientific exploration to the final formulation—undergoes rigorous analytical review and quality control. This disciplined approach reassures consumers and industry collaborators alike, fostering trust and establishing Chromadex as a reliable source of scientifically supported nutraceutical innovations.
Integrating Science and Consumer Wellness
The company’s approach is marked by a detailed understanding of biochemical processes and a commitment to translating this expertise into practical health solutions. With its diversified business segments, Chromadex not only addresses the needs of a broad consumer base but also solidifies its reputation among researchers and industry experts. Its dedicated exploration of key ingredients such as nicotinamide riboside, alongside other innovative compounds, continues to influence the realm of healthy aging and functional nutrition.
A jury in the United States District Court for the Central District of California ruled that Elysium Health breached its contract with ChromaDex, leading to damages of
ChromaDex Corp. (NASDAQ: CDXC) has formed a partnership with Sinopharm Xingsha Pharmaceuticals to facilitate cross-border sales of its product, Tru Niagen®, in mainland China. Sinopharm Xingsha is a key subsidiary of Sinopharm Group, involved in drug and health supplement distribution. With a projected 45.2% of China’s population over 50 by 2040, the demand for Tru Niagen® is expected to rise significantly. The collaboration also aims to obtain Health Food Registration in China, enhancing market accessibility for Tru Niagen®, a top NAD+ booster.
ChromaDex Corp. (NASDAQ:CDXC) announced significant preclinical findings from its External Research Program focusing on nicotinamide riboside (NR). Studies indicate NR's protective effects on retinal ganglion cells in glaucoma, improvement in Alzheimer’s disease models through enhanced brain NAD+ levels, and cardioprotective benefits in ischemia-reperfusion injury models. Additionally, ChromaDex is supporting clinical trials investigating NR's impact on neurological symptoms in ataxia-telangiectasia and skeletal muscle metabolism. These advancements highlight NR’s potential in addressing age-related conditions.
ChromaDex (NASDAQ:CDXC) announced plans to appeal a September 14 ruling in its patent infringement lawsuit against Elysium Health in the District Court of Delaware. The company holds exclusive rights to nicotinamide riboside (NR) through U.S. Patents 8,383,086 and 8,197,807. Additionally, ChromaDex's product Niagen® is supported by 13 clinical trials and approved by major regulatory bodies including the U.S. FDA and Health Canada. Another lawsuit against Elysium is set for trial on September 21 in California.
ChromaDex Corp. (NASDAQ:CDXC) reported Q2 2021 financial results showing net sales of $17.7 million, a 16% increase year-over-year. Tru Niagen® sales reached $15.4 million, up 31%. The gross margin improved to 61.1%, reflecting effective cost control. However, the company recorded a net loss of $(5.6) million or $(0.08) per share, compared to a loss of $(3.7) million last year. Adjusted EBITDA was $0.6 million, a slight improvement. The company anticipates continued revenue growth and is investing in R&D and marketing.
ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on August 3, 2021, at 4:30 p.m. ET to discuss its Q2 financial results ending June 30, 2021. The financial results will be released after the market closes on the same day. Interested participants should join 10 minutes early. The call will also provide a general business update. A replay will be available after the call. ChromaDex specializes in healthy aging and is known for its NAD+ precursor, nicotinamide riboside (Niagen®), featured in its Tru Niagen® product.
ChromaDex Corp. (NASDAQ:CDXC) announced results from four preclinical studies on nicotinamide riboside (NR), showcasing its benefits for healthy aging. Through its ChromaDex External Research Program (CERP™), the company has established over 225 research agreements, leading to 12 clinical and 66 preclinical studies. Notable findings include NR's role in preventing bone loss in aging mice and restoring metabolic capacity in aged stem cells. Additionally, NR is shown to reduce neuroinflammation and mitigate alcohol's harmful effects. ChromaDex has invested over $35 million in NR research and holds over 20 patents.
ChromaDex Corp. (NASDAQ:CDXC) has launched its flagship product, Tru Niagen®, in Walmart, making it available in 3,800 stores across the U.S. This marks Walmart as the first major U.S. retailer to stock the clinically studied NAD+ booster. Customers can choose between 100mg and 300mg serving sizes, both available for in-store and online purchases. Tru Niagen® aims to elevate NAD+ levels, which decline with age, by up to 50%. The product is supported by extensive safety and efficacy research and is recognized by multiple health authorities.
ChromaDex reported Q1 2021 net sales of $14.7 million, a 2% increase year-over-year, driven by a 12% growth in Tru Niagen® sales. The gross margin improved to 62.9%, up 500 basis points. However, the company posted a net loss of $7.4 million, or $0.12 per share, a deeper loss compared to Q1 2020's $5.9 million net loss. Operating expenses rose to $16.6 million, primarily due to increased selling and marketing costs. Looking ahead, ChromaDex anticipates steady revenue growth and continued margin improvement, with new strategic partnerships expected to boost sales.
ChromaDex Corp. (NASDAQ:CDXC) has entered into a strategic supply agreement for its patented ingredient Niagen® with Ro, a healthcare technology company. This agreement gives Ro rights to use Niagen® in specially formulated products aimed at promoting healthy aging. Niagen® is known to increase NAD+ levels, which decline with age. Both companies expressed enthusiasm about the partnership, with ChromaDex's focus on advancing health through research on nicotinamide adenine dinucleotide (NAD+).
FAQ
What is the current stock price of Chromadex (CDXC)?
What is the market cap of Chromadex (CDXC)?
What is Chromadex Corp's primary focus?
How does Chromadex generate its revenue?
What makes Chromadex's research unique?
What is the significance of nicotinamide riboside (NR) for Chromadex?
In which segments does Chromadex operate?
How does Chromadex ensure the quality and safety of its products?
How is Chromadex positioned within the competitive landscape?
What are the key benefits of Chromadex's integrated business model?
